1-(6-amino-purin-9-yl)-1,2-dideoxy-pentofuranose | 157049-41-7

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 1-(6-amino-purin-9-yl)-1,2-dideoxy-pentofuranose
• 英文别名: 2'-Deoxyadenosin；Deoxyadenosine；5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol
• CAS: 157049-41-7
• 化学式: C₁₀H₁₃N₅O₃
• mdl: MFCD00715211
• 分子量: 251.245
• InChiKey: OLXZPDWKRNYJJZ-UHFFFAOYSA-N

物化性质

• 沸点：
  636.0±65.0 °C(Predicted)
• 密度：
  1.91±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  119
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  1-(6-amino-purin-9-yl)-1,2-dideoxy-pentofuranose 在 咪唑 、 四丁基氟化铵 作用下， 以 四氢呋喃 、 氘代二甲亚砜 为溶剂， 反应 2.5h， 生成 2'-脱氧腺苷
  参考文献：
  名称：

  一种羟甲基的保护及脱保护方法

  摘要：

  本发明公开了一种羟甲基的保护及脱保护方法，包括保护过程和脱保护过程：所述保护过程为：将含羟甲基化合物和三异丙基氯硅烷通过缩合反应，在羟甲基上修饰三异丙基硅烷基团；所述脱保护过程为：修饰三异丙基硅烷基团的羟甲基化合物在四丁基氟化铵作用下进行脱保护基反应，得到含羟甲基化合物。该方法利用具有氟敏感性的三异丙基氯硅烷作为羟甲基保护基，具有高选择性和高结合率的特点，且极易在四丁基氟化铵作用下水解脱除，脱除效率高，整个保护和脱保护过程简单，条件温和，反应速率快，有利于扩大生产应用。

  公开号：

  CN117466963A

文献信息

• CFTR channel modulators
  申请人：Decout Jean-Luc

  公开号：US20060258612A1

  公开（公告）日：2006-11-16

  The invention concerns pharmaceutical formulas designed for the treatment of diseases related to CFTR channel dysfunction, such as cystic fibrosis, asthma or diarrhoea. These formulas contain a molecule, coming in the form of a zwitterion at physiological pH, with the formula: where X═N or P; Y═O or S; R 1 to R 7 represent: —, H, or carbon chains, substituted or not, which may contain heteroatoms; except for betaine.

  这项发明涉及针对与CFTR通道功能障碍相关的疾病（如囊性纤维化、哮喘或腹泻）设计的药物配方。这些配方含有一种分子，以生理pH值下的离子形式存在，其化学式为：其中X=N或P；Y=O或S；R1至R7代表：—、H或碳链，取代或未取代，可能含有杂原子；除了甜菜碱。
• Aminoglycoside-polyamine displacers and methods of use in displacement chromatography
  申请人：Rege Kaushal

  公开号：US20070049741A1

  公开（公告）日：2007-03-01

  Aminoglycoside-polyamines are disclosed along with methods of use thereof in displacement chromatography and as DNA-binding ligands. The aminoglycoside-polyamines are derivatives of carbohydrates, such as sugars, amino sugars, deoxysugars, glycosides, nucleosides and their substituted counterparts. The subject polyamines possess a group in place of at least one hydrogen atom of at least one hydroxyl group of the carbohydrate compound. In these compounds R 1 is an alkyl group or an azaalkyl group, and R 2 is a primary or secondary amino group.

  本文披露了氨基糖苷-多胺以及它们在置换色谱和作为DNA结合配体中的使用方法。氨基糖苷-多胺是碳水化合物的衍生物，例如糖，氨基糖，去氧糖，糖苷，核苷和它们的取代物。这些多胺具有取代至少一种碳水化合物化合物的至少一个羟基的氨基团。在这些化合物中，R1是烷基或氮杂基，R2是一级或二级氨基。
• [EN] BORANOPHOSPHATE DERIVATIVES FOR THE TREATMENT OF OSTEOARTHRITIS<br/>[FR] DÉRIVÉS DE BORANOPHOSPHATE DESTINÉS AU TRAITEMENT DE L'ARTHROSE
  申请人：UNIV BAR ILAN

  公开号：WO2012032513A1

  公开（公告）日：2012-03-15

  The present invention provides pharmaceutical compositions and methods for treatment and management of osteoarthritis using certain dinucleotide boranophosphate derivatives or nucleoside boranophosphate derivatives. The invention further provides particular diadenosine penta(ϒ-borano)phosphate derivative such as diadenosine 5',5''-P1,P5,α¸β-methylene-δ,ε- methylene-pentaphosphate-ϒ-borano and di-2'-deoxyadenosine 5',5''-P1,P5,α¸β-methylene-δ,ε-methylene pentaphosphate-ϒ-borano, and pharmaceutical compositions thereof.

  本发明提供了使用某些二核苷酸硼酸盐衍生物或核苷酸硼酸盐衍生物治疗和管理骨关节炎的药物组合物和方法。本发明进一步提供了特定的二腺苷五(ϒ-硼烷)磷酸盐衍生物，例如二腺苷5'，5''-P1，P5，α¸β-亚甲基-δ，ε-亚甲基-五磷酸盐-ϒ-硼烷和二-2'-去氧腺苷5'，5''-P1，P5，α¸β-亚甲基-δ，ε-亚甲基-五磷酸盐-ϒ-硼烷及其药物组合物。
• Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B
  申请人：Gosselin Gilles

  公开号：US20080188440A1

  公开（公告）日：2008-08-07

  This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-β-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2′-deoxy-β-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.

  该发明涉及一种治疗乙型肝炎感染宿主的方法，包括给予有效量的抗HBV生物活性2'-去氧-β-L-核糖核苷或其药学上可接受的盐或前药，其中2'-去氧-β-L-核糖核苷的化学式为：其中R选自H、直链、支链或环烷基、CO-烷基、CO-芳基、CO-烷氧基烷基、CO-芳氧基烷基、CO-取代芳基、烷基磺酰基、芳基磺酰基、芳基烷基磺酰基、氨基酸残基、单、二或三磷酸盐或磷酸衍生物；BASE是一种可以选择性地取代的嘌呤或嘧啶碱基。2'-去氧-β-L-核糖核苷或其药学上可接受的盐或前药可以单独或与另一种2'-去氧-β-L-核糖核苷或与另一种抗乙型肝炎药物联合使用。
• beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B
  申请人：Gosselin Gilles

  公开号：US20070087995A1

  公开（公告）日：2007-04-19

  This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-β-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2′-deoxy-β-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.

  本发明涉及一种治疗患有乙型肝炎的宿主的方法，包括给予有效量的抗HBV生物活性2'-脱氧-β-L-erythro-戊糖核苷或其药学上可接受的盐或前药，其中2'-脱氧-β-L-erythro-戊糖核苷的化学式为：其中R选自H，直链，支链或环烷基，CO-烷基，CO-芳基，CO-烷氧基烷基，CO-芳氧基烷基，CO-取代芳基，烷基磺酰基，芳基磺酰基，芳基烷基磺酰基，氨基酸残基，单磷酸、二磷酸或三磷酸，或磷酸衍生物；BASE是一种嘌呤或嘧啶碱基，可选择性地被取代。2'-脱氧-β-L-erythro-戊糖核苷或其药学上可接受的盐或前药可以单独或与另一种2'-脱氧-β-L-erythro-戊糖核苷或其他抗乙型肝炎药物联合使用。

表征谱图